Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.
Funder: National Institutes of Health
Due Dates: February 8, 2027 (New) | March 8, 2027 (Renewal/resubmission/revision) | June 9, 2027 (New) | July 9, 2027 (Renewal/resubmission/revision) | October 8, 2027 (New) | November 8, 2027 (Renewal/resubmission/revision) | February 7, 2028 (New) | March 7, 2028 (Renewal/resubmission/revision) | May 7, 2028 (Closing)
Funding Amounts: Award ceiling: $1,000,000; direct-cost cap: $1,000,000 annually; maximum project period: 5 years
Summary: Supports rigorous preclinical testing of repurposed drugs and combination therapies for Alzheimer’s disease and related dementias.
Key Information: Clinical trials and computational-only projects are not allowed; rapid, open sharing of data and resources is required.
The National Institute on Aging (NIA), part of NIH, administers this R01 program to advance drug repositioning and precision combination therapies for Alzheimer’s disease and related dementias (AD/ADRD). It supports rigorous preclinical proof-of-concept testing of drugs already used for other conditions and investigational drugs at different stages of clinical development, including candidates from failed Phase II/III trials.
Projects combine computational and experimental approaches to prioritize candidates and test efficacy, toxicity, target engagement, mechanisms of action, blood-brain barrier permeability, or pharmacokinetic/pharmacodynamic properties. Drug combinations may include non-pharmacologic interventions such as exercise, diet, sleep, or cognitive training. The goal is reproducible translational evidence supporting treatment and prevention of AD/ADRD, with particular interest in candidates identified through NIA’s ACTDRx AD program and approaches targeting disease-relevant molecular networks.